Butylated hydroxyanisole


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000737 Dna catabolic process, endonucleolytic Increases phenotype PMID:12160896
GO:0002523 Leukocyte migration involved in inflammatory response Increases phenotype PMID:29981020
GO:0002924 Negative regulation of humoral immune response mediated by circulating immunoglobulin Increases phenotype PMID:32179172
GO:0004364 Glutathione transferase activity Increases phenotype PMID:9794803
GO:0006702 Androgen biosynthetic process Increases phenotype PMID:27388148
GO:0006750 Glutathione biosynthetic process Decreases phenotype PMID:27718046
GO:0006882 Cellular zinc ion homeostasis Decreases phenotype PMID:28919410
GO:0006915 Apoptotic process Increases phenotype PMID:10353256; PMID:21362627; PMID:36007723
GO:0006974 Cellular response to dna damage stimulus Increases phenotype PMID:23027624
GO:0006979 Response to oxidative stress Increases phenotype PMID:12423650
GO:0007204 Positive regulation of cytosolic calcium ion concentration Increases phenotype PMID:25242404
GO:0008219 Cell death Increases phenotype PMID:25715797; PMID:27718046
GO:0008283 Cell population proliferation Decreases phenotype PMID:27718046
GO:0008284 Positive regulation of cell population proliferation Affects phenotype PMID:23535288
GO:0008285 Negative regulation of cell population proliferation Increases phenotype PMID:38657941
GO:0010917 Negative regulation of mitochondrial membrane potential Increases phenotype PMID:36007723
GO:0010940 Positive regulation of necrotic cell death Increases phenotype PMID:38657941
GO:0010942 Positive regulation of cell death Increases phenotype PMID:38657941
GO:0016049 Cell growth Decreases phenotype PMID:29486183
GO:0030336 Negative regulation of cell migration Increases phenotype PMID:38657941
GO:0030521 Androgen receptor signaling pathway Affects phenotype PMID:26812027; PMID:28115641
GO:0032689 Negative regulation of type ii interferon production Affects phenotype PMID:22250088
GO:0032753 Positive regulation of interleukin-4 production Increases phenotype PMID:32179172
GO:0033212 Iron import into cell Increases phenotype PMID:38657941
GO:0034440 Lipid oxidation Increases phenotype PMID:25242404
GO:0042921 Glucocorticoid receptor signaling pathway Affects phenotype PMID:28115641
GO:0045824 Negative regulation of innate immune response Increases phenotype PMID:32179172
GO:0046466 Membrane lipid catabolic process Increases phenotype PMID:2353831; PMID:36007723; PMID:6506766; PMID:9303565
GO:0048598 Embryonic morphogenesis Decreases phenotype PMID:28927898
GO:0050729 Positive regulation of inflammatory response Increases phenotype PMID:37045926
GO:0050765 Negative regulation of phagocytosis Increases phenotype PMID:32179172
GO:0050996 Positive regulation of lipid catabolic process Increases phenotype PMID:38657941
GO:0055074 Calcium ion homeostasis Affects phenotype PMID:27718046
GO:0061370 Testosterone biosynthetic process Increases phenotype PMID:27388148
GO:0070265 Necrotic cell death Increases phenotype PMID:29981020
GO:0072593 Reactive oxygen species metabolic process Increases phenotype PMID:25106854
GO:0097300 Programmed necrotic cell death Increases phenotype PMID:23261677
GO:0160020 Positive regulation of ferroptosis Increases phenotype PMID:38657941
GO:1901671 Positive regulation of superoxide dismutase activity Decreases phenotype PMID:25242404
GO:1903408 Positive regulation of p-type sodium:potassium-exchanging transporter activity Decreases phenotype PMID:25242404
GO:1903409 Reactive oxygen species biosynthetic process Increases phenotype PMID:27718046; PMID:36007723
GO:1903428 Positive regulation of reactive oxygen species biosynthetic process Increases phenotype PMID:38657941
GO:1903591 Negative regulation of lysozyme activity Increases phenotype PMID:32179172
GO:1903612 Positive regulation of calcium-dependent atpase activity Decreases phenotype PMID:25242404
GO:1905165 Regulation of lysosomal protein catabolic process Affects phenotype PMID:38657941
GO:2000439 Positive regulation of monocyte extravasation Increases phenotype PMID:37045926
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.